Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Dose of Caffeine in Naproxen/Caffeine Combination for Postsurgical Dental Pain
NCT04132336Phase 2Completed
- Sponsor
- Bayer
- Start
- Nov 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Aprol and caffeine in postoperative pain (7 arms), sponsored by Bayer. Primary endpoint: Sum of Pain Intensity Difference Over 8 Hours. Started Nov 2019; status: completed.
02
Drugs
Aprolcaffeine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT04132336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04132336.